Holen Sie sich die Stockscreener-App
231.95
0.45%
-1.06
Handel nachbörslich:
231.95
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$233.01
Offen:
$232.84
24-Stunden-Volumen:
839.24K
Relative Volume:
0.91
Marktkapitalisierung:
$25.60B
Einnahmen:
$11.28B
Nettoeinkommen (Verlust:
$1.07B
KGV:
25.59
EPS:
9.0657
Netto-Cashflow:
$1.33B
1W Leistung:
+0.05%
1M Leistung:
+7.52%
6M Leistung:
+25.26%
1J Leistung:
+35.76%
1-Tages-Spanne:
$230.54
$233.44
1-Wochen-Bereich:
$229.01
$240.13
52-Wochen-Spanne:
$170.53
$240.13
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
231.95 | 25.59B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
574.03 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
197.50 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.84 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
139.80 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
233.36 | 35.59B | 16.63B | 1.39B | 2.12B | 8.0674 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Insider at DGX (NYSE: DGX) plans sale of 1,600 common shares - Stock Titan
JPMorgan Adjusts Price Target on Quest Diagnostics to $250 From $220, Maintains Neutral Rating - marketscreener.com
DGX|Quest Diagnostics Inc|Price:231.750|Chg%:+3.890 - TradingKey
Quest Diagnostics Inc (DGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Form 4 Quest Diagnostics orporated For: 28 July By Investing.com - Investing.com South Africa
Quest Diagnostics Inc (DGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance
Quest Diagnostics (NYSE: DGX) SVP adds shares via dividend reinvestment plan - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP acquires 34.0000 shares via dividend reinvestment - Stock Titan
Rothschild & Co Redburn Adjusts Quest Diagnostics Price Target to $251 From $233, Maintains Buy Rating - Moomoo
Quest Diagnostics (DGX) Leads S&P 500 Healthcare Gainers with 8. - GuruFocus
Quest Diagnostics Incorporated (DGX) Stock forecasts - Yahoo Finance Singapore
Quest Diagnostics stock trades steady as earnings and diagnostics demand shape investor focus - Ad-hoc-news.de
Quest Diagnostics Inc (DGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quest Diagnostics Inc (DGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Truist Financial Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
Quest Diagnostics Inc (DGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quest Diagnostics Is Maintained at Outperform by Mizuho - Moomoo
Quest Diagnostics Inc (DGX) Cash Flow - TradingKey
DGX|Quest Diagnostics Inc|Price:227.860|Chg%:-0.050 - TradingKey
Quest Diagnostics Inc (DGX) Institutional Confidence - TradingKey
Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quest Diagnostics Inc (DGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q2 2026 Quest Diagnostics Inc Earnings Call Transcript - GuruFocus
Quest Diagnostics Q2 2026 Earnings: Net Income, Revenues, and Financial Highlights from SEC 10-Q Filing - Minichart
QUEST DIAGNOSTICS INC : TRUIST SECURITIES RAISES TARGET PRICE TO $250 FROM $225 - Bitget
UBS Adjusts Price Target on Quest Diagnostics to $232 From $220, Maintains Neutral Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $255 From $236, Maintains Neutral Rating - marketscreener.com
Barclays Raises Quest Diagnostics Price Target to $250 From $230, Maintains Overweight Rating - marketscreener.com
Mizuho Securities Adjusts Quest Diagnostics Price Target to $260 From $235, Maintains Outperform Rating - marketscreener.com
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $241.73, Implies 6% Upside - TradingView
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Deutsche Bank Adjusts Quest Diagnostics Price Target to $232 From $205, Maintains Hold Rating - marketscreener.com
Truist Raises Price Target on Quest Diagnostics to $250 From $225, Keeps Hold Rating - marketscreener.com
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $240.93, Implies 6% Upside - TradingView
Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results (NYSE:DGX) - Seeking Alpha
Morgan Stanley Adjusts PT on Quest Diagnostics to $260 From $226, Maintains Overweight Rating - marketscreener.com
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $239.27, Implies 5% Upside - TradingView
Quest Diagnostics stock trades steady as investors weigh recent earnings and diagnostics demand - Ad-hoc-news.de
Quest Diagnostics Inc (DGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trending Industry Today: Quest Diagnostics Leads Gains In CRO Stocks - Moomoo
Quest Diagnostics Inc (DGX) Shares Surge 8.6% -- What GF Score o - GuruFocus
Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary - Yahoo Finance
Quest Continues to Build on Its Hospital Lab Collaborations - Morningstar
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $229.6, Implies 9% Upside - TradingView
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: St - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics 2026: Revenue $3.04B, EPS $2.84— 10-Q Summary - TradingView
Quest Diagnostics (NYSE: DGX) lifts Q2 EPS to $2.84 on 10% revenue growth - Stock Titan
Quest Diagnostics Q2 Earnings Call Highlights - TradingView
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.98%
3.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):